TY - JOUR
T1 - Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children
T2 - SpIDnet observational multicentre study
AU - SpIDnet VE study group
AU - Savulescu, Camelia
AU - Krizova, Pavla
AU - Valentiner-Branth, Palle
AU - Ladhani, Shamez
AU - Rinta-Kokko, Hanna
AU - Levy, Corinne
AU - Mereckiene, Jolita
AU - Knol, Mirjam
AU - Winje, Brita A.
AU - Ciruela, Pilar
AU - de Miguel, Sara
AU - Guevara, Marcela
AU - MacDonald, Laura
AU - Kozakova, Jana
AU - Slotved, Hans Christian
AU - Fry, Norman K.
AU - Pekka Nuorti, J.
AU - Danis, Kostas
AU - Corcoran, Mary
AU - van der Ende, Arie
AU - Vestrheim, Didrik F.
AU - Munoz-Almagro, Carmen
AU - Sanz, Juan Carlos
AU - Castilla, Jesus
AU - Smith, Andrew
AU - Colzani, Edoardo
AU - Pastore Celentano, Lucia
AU - Hanquet, Germaine
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/6/23
Y1 - 2022/6/23
N2 - Background: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010–11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). Methods: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012–2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. Results: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0–88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8–96.1) < 12 months to 85.1% (72.0–92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7–94.7) against fatal PCV13 IPD, 64.5% (43.7–77.6), 83.2% (73.7–89.3) and 85.1% (67.6–93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3–94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4–92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2–96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and −14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. Conclusions: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.
AB - Background: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010–11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). Methods: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012–2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. Results: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0–88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8–96.1) < 12 months to 85.1% (72.0–92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7–94.7) against fatal PCV13 IPD, 64.5% (43.7–77.6), 83.2% (73.7–89.3) and 85.1% (67.6–93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3–94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4–92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2–96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and −14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. Conclusions: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.
KW - 10-valent pneumococcal vaccine
KW - 13-valent pneumococcal vaccine
KW - Invasive pneumococcal disease
KW - Pneumococcal Infections
KW - Serotype
KW - Streptococcus pneumoniae
UR - http://www.scopus.com/inward/record.url?scp=85131385873&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2022.05.011
DO - 10.1016/j.vaccine.2022.05.011
M3 - Article
C2 - 35637067
AN - SCOPUS:85131385873
SN - 0264-410X
VL - 40
SP - 3963
EP - 3974
JO - Vaccine
JF - Vaccine
IS - 29
ER -
